Oncolytic (replication-competent) adenoviruses as anticancer agents

Bibliography

• Cattaneo R, Miest T, Shashkova EV, Barry MA. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 2008;6:529-40
   PubMed Web of Science ®Google Scholar
• Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 2001;7:781-7
   PubMed Web of Science ®Google Scholar
• Lin E, Nemunaitis J. Oncolytic viral therapies. Cancer Gene Ther 2004;11:643-64
   PubMed Web of Science ®Google Scholar
• Wold WSM, Horwitz MS. Adenoviruses. In: Knipe DM, Howley PM, editors, Field's virology. 5th edition. Lippincott, Williams, & Wilkins, Philadelphia, PA; 2007. p. 2395-436
   Google Scholar
• Centers for Disease Control and Prevention. Acute respiratory disease associated with adenovirus serotype 14–four states, 2006-2007. Morb Mortal Wkly Rep 2007;56:1181-4
   PubMedGoogle Scholar
• Ison MG. Adenovirus infections in transplant recipients. Clin Infect Dis 2006;43:331-9
   PubMed Web of Science ®Google Scholar
• Kojaoghlanian T, Flomenberg P, Horwitz MS. The impact of adenovirus infection on the immunocompromised host. Rev Med Virol 2003;13:155-71
   PubMed Web of Science ®Google Scholar
• Berk AJ. Adenoviridae: the viruses and their replication. In: Knipe DM, Howley PM, editors, Field's virology. 5th edition. Lippincott, Williams, & Wilkins, Philadelphia, PA; 2007. p. 2355-94
   Google Scholar
• Russell WC. Adenoviruses: update on structure and function. J Gen Virol 2009;90:1-20
   PubMed Web of Science ®Google Scholar
• Bergelson J, Cunningham JA, Droguett G, Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 1997;275:1320-3
   PubMed Web of Science ®Google Scholar
• Dechecchi MC, Melotti P, Bonizzato A, Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J Virol 2001;75:8772-80
   PubMed Web of Science ®Google Scholar
• Wiethoff CM, Wodrich H, Gerace L, Nemerow GR. Adenovirus protein VI mediates membrane disruption following capsid disassembly. J Virol 2005;79:1992-2000
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Crystal RG, Leopold PL. Association of adenovirus with the microtubule organizing center. J Virol 2003;77:13275-87
   Google Scholar
• Pelka P, Ablack JN, Fonseca GJ, Intrinsic structural disorder in adenovirus E1A: a viral molecular hub linking multiple diverse processes. J Virol 2008;82:7252-63
   PubMed Web of Science ®Google Scholar
• Berk AJ. Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. Oncogene 2005;24:7673-85
   PubMed Web of Science ®Google Scholar
• Blackford AN, Grand RJ. Adenovirus E1B 55-kilodalton protein: multiple roles in viral infection and cell transformation. J Virol 2009;83:4000-12
   PubMed Web of Science ®Google Scholar
• Weitzman MD. Functions of the adenovirus E4 proteins and their impact on viral vectors. Front Biosci 2005;10:1106-17
   PubMed Web of Science ®Google Scholar
• Bett AJ, Haddara W, Prevec L, Graham FL. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA 1994;91:8802-6
   PubMed Web of Science ®Google Scholar
• He TC, Zhou S, da Costa LT, A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998;95:2509-14
   PubMed Web of Science ®Google Scholar
• O'Shea CC. Viruses – seeking and destroying the tumor program. Oncogene 2005;24:7640-55
   PubMed Web of Science ®Google Scholar
• Li Y, Pong RC, Bergelson JM, Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res 1999;59:325-30
   PubMed Web of Science ®Google Scholar
• Dmitriev I, Krasnykh V, Miller CR, An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998;72:9706-13
   PubMed Web of Science ®Google Scholar
• Shayakhmetov DM, Li ZY, Ni S, Lieber A. Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors. J Virol 2004;78:5368-81
   PubMed Web of Science ®Google Scholar
• Campos SK, Barry MA. Current advances and future challenges in Adenoviral vector biology and targeting. Curr Gene Ther 2007;7:189-204
   PubMed Web of Science ®Google Scholar
• Gaggar A, Shayakhmetov DM, Lieber A. CD46 is a cellular receptor for group B adenoviruses. Nat Med 2003;9:1408-12
   PubMed Web of Science ®Google Scholar
• Short JJ, Pereboev AV, Kawakami Y, Adenovirus serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptors. Virology 2004;322:349-59
   PubMed Web of Science ®Google Scholar
• Shayakhmetov DM, Papayannopoulou T, Stamatoyannopoulos G, Lieber A. Efficient gene transfer into human CD34+ cells by a retargeted adenovirus vector. J Virol 2000;74:2567-83
   PubMed Web of Science ®Google Scholar
• Krasnykh V, Belousova N, Korokhov N, Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin. J Virol 2001;75:4176-83
   PubMed Web of Science ®Google Scholar
• Mercier GT, Campbell JA, Chappell JD, A chimeric adenovirus vector encoding reovirus attachment protein sigma1 targets cells expressing junctional adhesion molecule 1. Proc Natl Acad Sci USA 2004;101:6188-93
   PubMed Web of Science ®Google Scholar
• Einfeld DA, Brough DE, Roelvink PW, Construction of a pseudoreceptor that mediates transduction by adenoviruses expressing a ligand in fiber or penton base. J Virol 1999;73:9130-6
   PubMed Web of Science ®Google Scholar
• Belousova N, Korokhov N, Krendelshchikova V, Genetically targeted adenovirus vector directed to CD40-expressing cells. J Virol 2003;77:11367-77
   PubMed Web of Science ®Google Scholar
• Krasnykh V, Dmitriev I, Mikheeva G, Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J Virol 1998;72:1844-52
   PubMed Web of Science ®Google Scholar
• Wickham TJ, Roelvink PW, Brough DE, Kovesdi I. Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nat Biotechnol 1996;14:1570-3
   PubMed Web of Science ®Google Scholar
• Dmitriev IP, Kashentseva EA, Curiel DT. Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX. J Virol 2002;76:6893-9
   PubMed Web of Science ®Google Scholar
• Vigne E, Mahfouz I, Dedieu JF, RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. J Virol 1999;73:5156-61
   PubMed Web of Science ®Google Scholar
• Zeng Y, Pinard M, Jaime J, A ligand-pseudoreceptor system based on de novo designed peptides for the generation of adenoviral vectors with altered tropism. J Gene Med 2008;10:355-67
   PubMed Web of Science ®Google Scholar
• Belousova N, Mikheeva G, Gelovani J, Krasnykh V. Modification of adenovirus capsid with a designed protein ligand yields a gene vector targeted to a major molecular marker of cancer. J Virol 2008;82:630-7
   PubMed Web of Science ®Google Scholar
• Rittner K, Schreiber V, Erbs P, Lusky M. Targeting of adenovirus vectors carrying a tumor cell-specific peptide: in vitro and in vivo studies. Cancer Gene Ther 2007;14:509-18
   PubMed Web of Science ®Google Scholar
• van Geer MA, Bakker CT, Koizumi N, Ephrin A2 receptor targeting does not increase adenoviral pancreatic cancer transduction in vivo. World J Gastroenterol 2009;15:2754-62
   PubMed Web of Science ®Google Scholar
• Kalyuzhniy O, Di Paolo NC, Silvestry M, Adenovirus serotype 5 hexon is critical for virus infection of heptocytes in vivo. Proc Natl Acad Sci USA 2008;105:5483-8
   PubMed Web of Science ®Google Scholar
• Waddington SN, Mcvey JH, Bhella D, Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008;132:397-409
   PubMed Web of Science ®Google Scholar
• Alba R, Bradshaw AC, Parker AL, Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood 2009;114:965-71
   PubMed Web of Science ®Google Scholar
• Kreppel F, Kochanek S. Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide. Mol Ther 2008;16:16-29
   PubMed Web of Science ®Google Scholar
• Fisher KD, Stallwood Y, Green NK, Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther 2001;8:341-8
   PubMed Web of Science ®Google Scholar
• Hofherr SE, Shashkova EV, Weaver EA, Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression. Mol Ther 2008;16:1276-82
   PubMed Web of Science ®Google Scholar
• Doronin K, Shashkova EV, May SM, Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus. Hum Gene Ther 2009;20:975-88
   PubMed Web of Science ®Google Scholar
• O'Riordan CR, Song A. PEGylated adenovirus for targeted gene therapy. Methods Mol Biol 2008;434:133-60
   PubMedGoogle Scholar
• Park JW, Mok H, Park TG. Epidermal growth factor (EGF) receptor targeted delivery of PEGylated adenovirus. Biochem Biophys Res Commun 2008;366:769-74
   PubMed Web of Science ®Google Scholar
• Eto Y, Yoshioka Y, Mukai Y, Development of PEGylated adenovirus vector with targeting ligand. Int J Pharm 2008;354:3-8
   PubMedGoogle Scholar
• Sims K, Ahmed Z, Read ML, In vitro evaluation of a ‘stealth’ adenoviral vector for targeted gene delivery to adult mammalian neurones. J Gene Med 2009;11:335-44
   PubMed Web of Science ®Google Scholar
• Steel JC, Cavanagh HM, Burton MA, Increased tumor localization and reduced immune response to adenoviral vector formulated with the liposome DDAB/DOPE. Eur J Pharm Sci 2007;30:398-405
   PubMed Web of Science ®Google Scholar
• Lee EM, Hong SH, Lee YJ, Liposome-complexed adenoviral gene transfer in cancer cells expressing various levels of coxsackievirus and adenovirus receptor. J Cancer Res Clin Oncol 2004;130:169-77
   PubMed Web of Science ®Google Scholar
• Kashentseva EA, Douglas JT, Zinn KR, Targeting of adenovirus serotype 5 pseudotyped with short fiber from serotype 41 to c-erbB2-positive cells using bispecific single-chain diabody. J Mol Biol 2009;388:443-61
   PubMed Web of Science ®Google Scholar
• van der Poel HG, Molenaar B, Van Beusechem VW, Epidermal growth factor receptor targeting of replication competent adenovirus enhances cytotoxicity in bladder cancer. J Urol 2002;168:266-72
   PubMed Web of Science ®Google Scholar
• Hall B, Dembinski J, Sasser AK, Mesenchymal stem cells in cancer: tumor-associated fibroblasts and cell-based delivery vehicles. Int J Hematol 2007;86:8-16
   PubMed Web of Science ®Google Scholar
• Komarova S, Kawakami Y, Stoff-Khalili MA, Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther 2006;5:755-66
   PubMed Web of Science ®Google Scholar
• Hakkarainen T, Sarkioja M, Lehenkari P, Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors. Human Gene Ther 2007;18:627-41
   PubMed Web of Science ®Google Scholar
• Bischoff JR, Kirn DH, Williams A, An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996;274:373-6
   PubMed Web of Science ®Google Scholar
• Harada JN, Berk AJ. p53-independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. J Virol 1999;73:5333-44
   PubMed Web of Science ®Google Scholar
• O'Shea CC, Johnson L, Bagus B, Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 2004;6:611-23
   PubMed Web of Science ®Google Scholar
• Doronin K, Toth K, Kuppuswamy M, Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J Virol 2000;74:6147-55
   PubMed Web of Science ®Google Scholar
• Fueyo J, Gomez-Manzano C, Alemany R, A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000;19:2-12
   PubMed Web of Science ®Google Scholar
• Heise C, Hermiston T, Johnson L, An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 2000;6:1134-9
   PubMed Web of Science ®Google Scholar
• Nelson JE, Kay MA. Persistence of recombinant adenovirus in vivo is not dependent on vector DNA replication. J Virol 1997;71:8902-7
   PubMed Web of Science ®Google Scholar
• Hurtado PA, Wang X, Sipo I, Viral and nonviral factors causing nonspecific replication of tumor- and tissue-specific promoter-dependent oncolytic adenoviruses. Mol Ther 2005;11:563-77
   PubMed Web of Science ®Google Scholar
• Toth K, Djeha H, Ying B, An oncolytic adenovirus vector combining enhanced cell-to-cell spreading, mediated by the ADP cytolytic protein, with selective replication in cancer cells with deregulated Wnt signaling. Cancer Res 2004;64:3638-44
   PubMed Web of Science ®Google Scholar
• Ramachandra M, Rahman A, Zou A, Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy. Nat Biotech 2001;19:1035-41
   PubMed Web of Science ®Google Scholar
• Lansdorp PM. Telomeres and disease. EMBO J 2009;28:2532-40
   PubMed Web of Science ®Google Scholar
• Cascallo M, Capella G, Mazo A, Alemany R. Ras-dependent oncolysis with an adenovirus VAI mutant. Cancer Res 2003;63:5544-50
   PubMed Web of Science ®Google Scholar
• Wang Y, Xue SA, Hallden G, Virus-associated RNA I-deleted adenovirus, a potential oncolytic agent targeting EBV-associated tumors. Cancer Res 2005;65:1523-31
   PubMed Web of Science ®Google Scholar
• Cascallo M, Gros A, Bayo N, Deletion of VAI and VAII RNA genes in the design of oncolytic adenoviruses. Hum Gene Ther 2006;17:929-40
   Google Scholar
• Cawood R, Chen HH, Carroll F, Use of tissue-specific microRNA to control pathology of wild-type adenovirus without attenuation of its ability to kill cancer cells. PLoS Pathog 2009;5:e1000440
   PubMed Web of Science ®Google Scholar
• Ylosmaki E, Hakkarainen T, Hemminki A, Generation of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specific MicroRNA. J Virol 2008;82:11009-15
   PubMed Web of Science ®Google Scholar
• Jin F, Kretschmer PJ, Hermiston TW. Identification of novel insertion sites in the Ad5 genome that utilize the Ad splicing machinery for therapeutic gene expression. Mol Ther 2005;12:1052-63
   PubMed Web of Science ®Google Scholar
• Sauthoff H, Hu J, Maca C, Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points. Hum Gene Ther 2003;14:425-33
   PubMed Web of Science ®Google Scholar
• Ganesh S, Gonzalez EM, Idamakanti N, Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. Cancer Res 2007;67:4399-407. Erratum appears in Cancer Res 2007 Jun 15; 67(12):5998
   PubMed Web of Science ®Google Scholar
• Kim JH, Lee YS, Kim H, Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. J Natl Cancer Inst 2006;98:1482-93
   PubMed Web of Science ®Google Scholar
• Galanis E, Bateman A, Johnson K, Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas. Hum Gene Ther 2001;12:811-21
   PubMed Web of Science ®Google Scholar
• Doronin K, Toth K, Kuppuswamy M, Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus. Virology 2003;305:378-87
   PubMed Web of Science ®Google Scholar
• Chen MJ, Green NK, Reynolds GM, Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector. Gene Ther 2004;11:1126-36
   PubMed Web of Science ®Google Scholar
• Freytag SO, Rogulski KR, Paielli DL, A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther 1998;9:1323-33
   PubMed Web of Science ®Google Scholar
• Freytag SO, Barton KN, Brown SL, Replication-competent adenovirus-mediated suicide gene therapy with radiation in a preclinical model of pancreatic cancer. Mol Ther 2007;15:1600-6
   PubMed Web of Science ®Google Scholar
• Endo Y, Sakai R, Ouchi M, Virus-mediated oncolysis induces danger signal and stimulates cytotoxic T-lymphocyte activity via proteasome activator upregulation. Oncogene 2008;27:2375-81
   PubMed Web of Science ®Google Scholar
• Dougan M, Dranoff G. Immune therapy for cancer. Ann Rev Immunol 2009;27:83-117
   PubMed Web of Science ®Google Scholar
• Lei N, Shen FB, Chang JH, An oncolytic adenovirus expressing granulocyte macrophage colony-stimulating factor shows improved specificity and efficacy for treating human solid tumors. Cancer Gene Ther 2009;16:33-43
   PubMed Web of Science ®Google Scholar
• Ramesh N, Ge Y, Ennist DL, CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor–armed oncolytic adenovirus for the treatment of bladder cancer. Clin Cancer Res 2006;12:305-13
   PubMed Web of Science ®Google Scholar
• He LF, Gu JF, Tang WH, Significant antitumor activity of oncolytic adenovirus expressing human interferon-beta for hepatocellular carcinoma. J Gene Med 2008;10:983-92
   PubMed Web of Science ®Google Scholar
• Su C, Peng L, Sham J, Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-gamma gene yields efficient antitumor activity in immunodeficient and immunocompetent mice. Mol Ther 2006;13:918-27
   PubMed Web of Science ®Google Scholar
• Shashkova EV, Spencer JF, Wold WSM, Doronin K. Targeting interferon-alpha increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus. Mol Ther 2007;15:598-607
   PubMed Web of Science ®Google Scholar
• Lapteva N, Aldrich M, Weksberg D, Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity. J Immunother 2009;32:145-56
   PubMed Web of Science ®Google Scholar
• Lee YS, Kim JH, Choi KJ, Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model. Clin Cancer Res 2006;12:5859-68
   PubMed Web of Science ®Google Scholar
• Haviv YS, Blackwell JL, Li H, Heat shock and heat shock protein 70i enhance the oncolytic effect of replicative adenovirus. Cancer Res 2001;61:8361-5
   PubMed Web of Science ®Google Scholar
• Hawkins LK, Hermiston TW. Gene delivery from the E3 region of replicating human adenovirus: evaluation of the E3B region. Gene Ther 2001;8:1142-8
   PubMed Web of Science ®Google Scholar
• Shashkova EV, Kuppuswamy MN, Wold WS, Doronin K. Anticancer activity of oncolytic adenovirus vector armed with IFN-alpha and ADP is enhanced by pharmacologically controlled expression of TRAIL. Cancer Gene Ther 2008;15:72
   Web of Science ®Google Scholar
• Sova P, Ren XW, Ni S, A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Mol Ther 2004;9:496-509
   PubMed Web of Science ®Google Scholar
• Tagawa M, Kawamura K, Shimozato O, Virology- and immunology-based gene therapy for cancer. Cancer Immunol Immunother 2006;55:1420-5
   PubMed Web of Science ®Google Scholar
• Hanna E, Quick J, Libutti SK. The tumour microenvironment: a novel target for cancer therapy. Oral Dis 2009;15:8-17
   PubMed Web of Science ®Google Scholar
• Hood JD, Bednarski M, Frausto R, Tumor regression by targeted gene delivery to the neovasculature. Science 2002;296:2404-7
   PubMed Web of Science ®Google Scholar
• Li G, Sham J, Yang J, Potent antitumor efficacy of an E1B 55kDa-deficient adenovirus carrying murine endostatin in hepatocellular carcinoma. Int J Cancer 2005;113:640-8
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zou W, Wang J, Suppression of tumor growth by oncolytic adenovirus-mediated delivery of an antiangiogenic gene, soluble FLT-1. Mol Ther 2004;11:553-62
   Web of Science ®Google Scholar
• Yoo JY, Kim JH, Kwon YG, VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth. Mol Ther 2007;15:295-302
   PubMed Web of Science ®Google Scholar
• Sarkar D, Lebedeva IV, Su ZZ, Eradication of therapy-resistant human prostate tumors using a cancer terminator virus. Cancer Res 2007;67:5434-42
   PubMed Web of Science ®Google Scholar
• Gros A, Martinez-Quintanilla J, Puig C, Bioselection of a gain of function mutation that enhances adenovirus 5 release and improves its antitumoral potency. Cancer Res 2008;68:8928-37
   PubMed Web of Science ®Google Scholar
• Subramanian T, Vijayalingam S, Chinnadurai G. Genetic identification of adenovirus type 5 genes that influence viral spread. J Virol 2006;80:2000-12
   Google Scholar
• Yan W, Kitzes G, Dormishian F, Developing novel oncolytic adenoviruses through bioselection. J Virol 2003;77:2640-50
   PubMed Web of Science ®Google Scholar
• Kuhn I, Harden P, Bauzon M, Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS One 2008;3:e2409
   PubMed Web of Science ®Google Scholar
• Spencer JF, Sagartz JE, Wold WSM, Toth K. New pancreatic carcinoma model for studying oncolytic adenoviruses in the permissive Syrian hamster. Cancer Gene Ther 2009;16:912-22
   PubMed Web of Science ®Google Scholar
• Thomas MA, Spencer JF, La Regina MC, Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res 2006;66:1270-6
   PubMed Web of Science ®Google Scholar
• Thomas MA, Spencer JF, Toth K, Immunosuppression enhances oncolytic adenovirus replication and anti tumor efficacy in the Syrian hamster model. Mol Ther 2008;16:1665-73
   PubMed Web of Science ®Google Scholar
• Dhar D, Spencer JF, Toth K, Wold WSM. Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters. J Virol 2009;83:2130-9
   PubMed Web of Science ®Google Scholar
• Dhar D, Spencer JF, Toth K, Wold WSM. Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by oncolytic adenovirus vector. Mol Ther 2009;17:1724-32
   PubMed Web of Science ®Google Scholar
• Thomas MA, Spencer JF, Wold WSM. The use of the syrian hamster as an animal model for oncolytic adenovirus vectors. In: Tollefson AE, Wold WSM, editors, Adenovirus methods and protocols. 2nd edition. Humana Press; 2005
   Google Scholar
• Toth K, Spencer JF, Tollefson AE, Cotton rat tumor model for the evaluation of oncolytic adenoviruses. Hum Gene Ther 2005;16:139-46
   PubMed Web of Science ®Google Scholar
• Shayakhmetov DM, Li ZY, Ni S, Lieber A. Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases. Cancer Res 2002;62:1063-8
   PubMed Web of Science ®Google Scholar
• Barton KN, Xia X, Yan H, A quantitative method for measuring gene expression magnitude and volume delivered by gene therapy vectors. Mol Ther 2004;9:625-31
   PubMed Web of Science ®Google Scholar
• Reid T, Warren R, Kirn D. Intravascular adenoviral agents in cancer patients: Lessons from clinical trials. Cancer Gene Ther 2002;9:979-86
   PubMed Web of Science ®Google Scholar
• Shen BH, Bauzon M, Hermiston TW. The effect of hypoxia on the uptake, replication and lytic potential of group B adenovirus type 3 (Ad3) and type 11p (Ad11p). Gene Ther 2006;13:986-90
   PubMed Web of Science ®Google Scholar
• Bortolanza S, Bunuales M, Alzuguren P, Influence of the E3 6.7k/gp19K region on adenovirus replicaton in immunocompetent Syrian hamsters. Hum Gene Ther 2007;18:1066
   Web of Science ®Google Scholar
• Hartman ZC, Appledorn DM, Amalfitano A. Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res 2008;132:1-14
   PubMed Web of Science ®Google Scholar
• Wildner O, Morris JC. Subcutaneous administration of a replication-competent adenovirus expressing HSV-tk to cotton rats: dissemination, persistence, shedding, and pathogenicity. Hum Gene Ther 2002;13:101-12
   PubMed Web of Science ®Google Scholar
• Wildner O. Comparison of replication-selective, oncolytic viruses for the treatment of human cancers. Curr Opin Mol Ther 2003;5:351-61
   PubMed Web of Science ®Google Scholar
• Bortolanza S, Alzuguren P, Bunuales M, Human adenovirus replicates in immunocompetent models of pancreatic cancer in Syrian hamsters. Hum Gene Ther 2007;18:681-90
   PubMed Web of Science ®Google Scholar
• Sonabend AM, Ulasov IV, Han Y, Biodistribution of an oncolytic adenovirus after intracranial injection in permissive animals: a comparative study of Syrian hamsters and cotton rats. Cancer Gene Ther 2008;16:362-72
   PubMed Web of Science ®Google Scholar
• Lichtenstein DL, Spencer JF, Doronin K, An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector. Cancer Gene Ther 2009;16:644-54
   PubMed Web of Science ®Google Scholar
• Ying B, Toth K, Spencer JF, INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies. Cancer Gene Ther 2009;16:625-37
   PubMed Web of Science ®Google Scholar
• Toth K, Spencer JF, Dhar D, Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model. Proc Natl Acad Sci USA 2008;105:7293-7
   PubMed Web of Science ®Google Scholar
• Kumar S, Gao L, Yeagy B, Reid T. Virus combinations and chemotherapy for the treatment of human cancers. Curr Opin Mol Ther 2008;10:371-9
   PubMed Web of Science ®Google Scholar
• Alemany R. Cancer selective adenoviruses. Mol Aspects Med 2007;28:42-58
   PubMed Web of Science ®Google Scholar
• Crompton AM, Kirn DH. From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development. Curr Cancer Drug Targets 2007;7:133-9
   PubMed Web of Science ®Google Scholar
• Habib N, Salama H, Abd El Latif Abu Median, Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma. Cancer Gene Ther 2002;9:254-9
   PubMed Web of Science ®Google Scholar
• Au T, Thorne S, Korn WM, Minimal hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor in normal liver. Cancer Gene Ther 2007;14:139-50
   PubMed Web of Science ®Google Scholar
• Ganly I, Kirn D, Eckhardt G, A Phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 2000;6:798-806
   PubMed Web of Science ®Google Scholar
• Khuri FR, Nemunaitis J, Ganly I, A controlled trial of intratumoral ONYX-015, a selectively replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000;6:879-85
   PubMed Web of Science ®Google Scholar
• Morley S, MacDonald G, Kirn D, The dl1520 virus is found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma. Clin Cancer Res 2004;10:4357-62
   PubMed Web of Science ®Google Scholar
• Reid T, Galanis E, Abbruzzese J, Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther 2001;8:1618-26
   PubMed Web of Science ®Google Scholar
• Reid TR, Freeman S, Post L, Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. Cancer Gene Ther 2005;12:673-81
   PubMed Web of Science ®Google Scholar
• Sze DY, Freeman SM, Slonim SM, Dr. Gary J. Becker Young Investigator Award: intraarterial adenovirus for metastatic gastrointestinal cancer: activity, radiographic response, and survival. J Vasc Interv Radiol 2003;14:279-90
   PubMed Web of Science ®Google Scholar
• Reid T, Galanis E, Abbruzzese J, Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 2002;62:6070-9
   PubMed Web of Science ®Google Scholar
• Lu W, Zheng S, Li XF, Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial. World J Gastroenterol 2004;10:3634-8
   PubMed Web of Science ®Google Scholar
• Jia H, Kling J. China offers alternative gateway for experimental drugs. Nat Biotechnol 2006;24:117-8
   PubMed Web of Science ®Google Scholar
• Yu W, Fang H. Clinical trials with oncolytic adenovirus in China. Current Cancer Drug Targets 2007;7:141-8
   PubMed Web of Science ®Google Scholar
• Garber K. China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst 2006;98:298-300
   PubMed Web of Science ®Google Scholar
• Freytag SO, Stricker H, Movsas B, Kim JH. Prostate cancer gene therapy clinical trials. Mol Ther 2007;15:1042-52
   PubMed Web of Science ®Google Scholar
• Freytag SO, Khil M, Stricker H, Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 2002;62:4968-76
   PubMed Web of Science ®Google Scholar
• Freytag SO, Stricker H, Pegg J, Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res 2003;63:7497-506
   PubMed Web of Science ®Google Scholar
• Freytag SO, Stricker H, Peabody J, Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer. Mol Ther 2007;15:636-42
   PubMed Web of Science ®Google Scholar
• Freytag SO, Movsas B, Aref I, Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. Mol Ther 2007;15:1016-23
   PubMed Web of Science ®Google Scholar
• DeWeese TL, van der Poel H, Li S, A Phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 2001;61:7464-72
   PubMed Web of Science ®Google Scholar
• Small EJ, Carducci MA, Burke JM, A Phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther 2006;14:107-17
   PubMed Web of Science ®Google Scholar
• Raper SE, Chirmule N, Lee FS, Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003;80:148-58
   PubMed Web of Science ®Google Scholar
• Shirakawa T. The current status of adenovirus-based cancer gene therapy. Mol Cells 2008;25:462-6
   PubMed Web of Science ®Google Scholar
• Vaillancourt M, Atencio I, Quijano E, Inefficient killing of quiescent human epithelial cells by replicating adenoviruses: potential implications for their use as oncolytic agents. Cancer Gene Ther 2005;12:691-8
   PubMed Web of Science ®Google Scholar
• Rodriguez R, Schuur ER, Lim HY, Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997;57:2559-63
   PubMed Web of Science ®Google Scholar
• Hallenbeck PL, Chang Y-N, Hay C, A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum Gene Ther 1999;10:1721-33
   PubMed Web of Science ®Google Scholar
• Li Y, De-Chao Y, Amin P, A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res 2001;61:6428-36
   PubMed Web of Science ®Google Scholar
• Yu DC, Sakamoto GT, Henderson DR. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of Calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res 1999;59:1498-504
   PubMed Web of Science ®Google Scholar
• Hernandez-Alcoceba R, Pihalja M, Wicha MS, Clarke MF. A novel, conditionally replicative adenovirus for the treatment of breast cancer that allows controlled replication of E1a-deleted adenoviral vectors. Hum Gene Ther 2000;11:2009-24
   PubMed Web of Science ®Google Scholar
• Kurihara T, Brough DE, Kovesdi I, Kufe DW. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest 2000;106:763-71
   PubMed Web of Science ®Google Scholar
• Doronin K, Kuppuswamy M, Toth K, Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy. J Virol 2001;75:3314-24
   PubMed Web of Science ®Google Scholar
• Brunori M, Malerba M, Kashiwazaki H, Iggo R. Replicating adenoviruses that target tumors with constitutive activation of the wnt signaling pathway. J Virol 2001;75:2857-65
   PubMed Web of Science ®Google Scholar
• Matsubara S, Wada Y, Gardner TA, A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Cancer Res 2001;61:6012-9
   PubMed Web of Science ®Google Scholar
• Adachi Y, Reynolds PN, Yamamoto M, A midkine promoter-based conditionally replicative adenovirus for treatment of pediatric solid tumors and bone marrow tumor purging. Cancer Res 2001;61:7882-8
   PubMed Web of Science ®Google Scholar
• Savontaus MJ, Sauter BV, Huang TG, Woo SL. Transcriptional targeting of conditionally replicating adenovirus to dividing endothelial cells. Gene Ther 2002;9:972-9
   PubMed Web of Science ®Google Scholar
• Zhang J, Ramesh N, Chen Y, Identification of human uroplakin II promoter and its use in the construction of CG8840, a urothelium-specific adenovirus variant that eliminates established bladder tumors in combination with docetaxel. Cancer Res 2002;62:3743-50
   PubMed Web of Science ®Google Scholar
• Johnson L, Shen A, Boyle L, Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell 2002;1:325-37
   PubMed Web of Science ®Google Scholar
• Hernandez-Alcoceba R, Pihalja M, Qian D, Clarke MF. New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication. Hum Gene Ther 2002;13:1737-50
   PubMed Web of Science ®Google Scholar
• Nettelbeck DM, Rivera AA, Balague C, Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. Cancer Res 2002;62:4663-70
   PubMed Web of Science ®Google Scholar
• Zhang L, Akbulut H, Tang Y, Adenoviral vectors with E1A regulated by tumor-specific promoters are selectively cytolytic for breast cancer and melanoma. Mol Ther 2002;6:386-93
   PubMed Web of Science ®Google Scholar
• Huang TG, Savontaus MJ, Shinozaki K, Telomerase-dependent oncolytic adenovirus for cancer treatment. Gene Ther 2003;10:1241-7
   PubMed Web of Science ®Google Scholar
• Kuppuswamy M, Spencer JF, Doronin K, Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression. Gene Ther 2005;12:1608-17
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Davydova J, Wang M, Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology 2003;125:1203-18
   PubMed Web of Science ®Google Scholar
• Li Y, Chen Y, Dilley J, Carcinoembryonic antigen-producing cell-specific oncolytic adenovirus, OV798, for colorectal cancer therapy. Molecular Cancer Therapeutics 2003;2:1003-9
   PubMed Web of Science ®Google Scholar
• Zhu ZB, Makhija SK, Lu B, Incorporating the survivin promoter in an infectivity enhanced CRAd-analysis of oncolysis and anti-tumor effects in vitro and in vivo. Int J Oncol 2005;27:237-46
   PubMed Web of Science ®Google Scholar
• Sarkar D, Su ZZ, Vozhilla N, Targeted virus replication plus immunotherapy eradicates primary and distant pancreatic tumors in nude mice. Cancer Res 2005;65:9056-63
   PubMed Web of Science ®Google Scholar
• Hoffmann D, Meyer B, Wildner O. Improved glioblastoma treatment with Ad5/35 fiber chimeric conditionally replicating adenoviruses. J Gene Med 2007;9:764-78
   PubMed Web of Science ®Google Scholar
• Tsuruta Y, Pereboeva L, Breidenbach M, A fiber-modified mesothelin promoter-based conditionally replicating adenovirus for treatment of ovarian cancer. Clin Cancer Res 2008;14:3582-8
   PubMed Web of Science ®Google Scholar
• Leja J, Dzojic H, Gustafson E, A novel chromogranin-A promoter-driven oncolytic adenovirus for midgut carcinoid therapy. Clin Cancer Res 2007;13:2455-62
   PubMed Web of Science ®Google Scholar